Skip to main content
SpringerLink
Log in

Epidemiologie und neue Richtwerte zur Behandlung der Hyperlipoproteinämien

  • Conference paper
Aktuelle Gesichtspunkte der Hyperlipoproteinämien

  • 16 Accesses

Zusammenfassung

Erkrankungen des Herz-Kreislaufsystems zeichnen in der westlichen Welt noch immer für etwa die Hälfte aller Todesfälle verantwortlich. Die kausale Beziehung zwischen Störungen im Lipidstoffwechsel und Entwicklung arteriosklerotischer Gefäßerkrankungen wird heute fast universell akzeptiert. Die Grundlagen für unser Verständnis darüber wurden in großangelegten epidemiologischen Studien erarbeitet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Blankenborn DH, Nessim SA, Johnson RL et al (1987) Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257: 3233–3240

    Article  Google Scholar 

  2. Brown MS, Goldstein JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232: 34–47

    Article  PubMed  CAS  Google Scholar 

  3. Carlson LA, Böttiger LE (1985) Risk factors for ischaemic heart disease in men and women: results of the 19-year follow-up of the Stockholm prospective study. Acta Med Scand 218: 207–211

    Article  PubMed  CAS  Google Scholar 

  4. Castelli WP, Garrison RJ, Wilson PWF et al (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 256: 2835–2838

    Article  PubMed  CAS  Google Scholar 

  5. Chen CH, Albers JJ (1985) Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3 and A-IV isolated from human plasma. Biochim Biophys Acta 836: 279–285

    PubMed  CAS  Google Scholar 

  6. Europäischer Konsens zur Primärprävention der KHK (1986). MMW Extrablatt 48: 1–4

    Google Scholar 

  7. Fielding CJ, Shore VG, Fielding PE (1972) A protein cofactor of lecithin: cholesterol acyltransferase. Biochem Biophys Res Commun 46: 1493–1498

    Article  PubMed  CAS  Google Scholar 

  8. Frick MH, Elo O, Haapa K et al (1987) Helsinki-heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317: 1237–1245

    Article  PubMed  CAS  Google Scholar 

  9. Glueck CJ, Fallat RW, Millet F et al (1975) Familial hyperalpha-lipoproteinemia: studies in eighteen kindreds. Metabolism 24: 1243–1265

    Article  PubMed  CAS  Google Scholar 

  10. Goldbourt V, Holtzman E, Neufeld HN (1985) Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J 290: 1239–1243

    Article  CAS  Google Scholar 

  11. Gordon T, Castelli WP, Hjortland MC et al (1977) High density lipoprotein as a protective factor against coronary heart disease. Am J Med 62: 707–714

    Article  PubMed  CAS  Google Scholar 

  12. Hui D, Brecht WJ, Hall EA et al (1986) Isolation and characterization of the apolipoprotein E receptor from canine and human liver. J Biol Chem 261: 4256–4267

    CAS  Google Scholar 

  13. Innerarity TL, Pitas RE, Mahley RW (1979) Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem 254: 4186–4190

    PubMed  CAS  Google Scholar 

  14. Kannel WB, Castelli WP, Gordon T et al (1971) Serum cholesterol, lipoproteins, and risk of coronary heart disease: the Framingham study. Ann Intern Med 74: 1–12

    PubMed  CAS  Google Scholar 

  15. Kannel WB, Castelli WP, Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Ann Intern Med 90: 85–91

    PubMed  CAS  Google Scholar 

  16. Kovanen PT, Bilheimer DW, Goldstein JL et al (1981) Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 78: 1194–1198

    Article  PubMed  CAS  Google Scholar 

  17. Lipid Research Clinics Program (1984 a) The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251: 351–364

    Google Scholar 

  18. Lipid Research Clinics Program (1984 b) The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374

    Google Scholar 

  19. Mahley, RW, Hui DY, Innerarity TL, Weisgraber KH (1981) Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo B, E and apo E receptors. J Clin Invest 68: 1197–1206

    CAS  Google Scholar 

  20. Miller GJ, Miller NE (1975) Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1: 16–19

    Article  PubMed  CAS  Google Scholar 

  21. Miller NE, Forde OH, Thelle DS, Mjos OD (1977) The Tromso heart-study: high-density lipoprotein and coronary heart-disease: a prospective casecontrol study. Lancet 1: 965–967

    Article  PubMed  CAS  Google Scholar 

  22. Multiple Risk Faktor Intervention Trial Group (1982) Multiple risk factor intervention trial: risk factor changes and morbidity results. JAMA 248: 1465–1467

    Article  Google Scholar 

  23. Nielsson-Ehle P, Garfinkel AS, Schotz MC (1980) Lipolytic enzymes and plasma lipoprotein metabolism. Am Rev Biochem 49: 667–693

    Article  Google Scholar 

  24. Oliver MF (1982) Risks of correcting the risks of coronary disease and stroke with drugs. N Engl J Med 306: 297–298

    Article  PubMed  CAS  Google Scholar 

  25. Phillips MC, Johnson WJ, Rothblat GH (1987) Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta 906: 223–276

    PubMed  CAS  Google Scholar 

  26. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project research group (1978). J Chronic Dis 31: 201–306

    Google Scholar 

  27. Rhoads GG, Gulbrandsen CL, Kagan A (1976) Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 294: 293–298

    Article  PubMed  CAS  Google Scholar 

  28. Ross R (1986) The pathogenesis of atherosclerosis - an update. N Engl J Med 314: 488–500

    Article  PubMed  CAS  Google Scholar 

  29. Solberg LA, Strong JP (1983) Risk factors and athersclerotic lesions: a review of autopsy studies. Arteriosclerosis 3: 187–198

    Article  PubMed  CAS  Google Scholar 

  30. Soutar AK, Garner CW, Baker HN et al (1975) Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry 14: 3057–3064

    Article  PubMed  CAS  Google Scholar 

  31. Spady DK, Bilheimer DW, Dietschy JM (1983) Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster. Proc Natl Acad Sci USA 80: 3499–3503

    Article  PubMed  CAS  Google Scholar 

  32. Stamler J, Wentworth D, Neaton J (1986) Is the relationship between serum cholesterol and risk of death from coronary heart disease continuous or graded? JAMA 256: 2823–2828

    Article  PubMed  CAS  Google Scholar 

  33. Steinberg D, NIH Consensus Development Panel (1985) Lowering blood cholesterol to prevent heart disease. JAMA 253: 2080–2086

    Google Scholar 

  34. Steinmetz A, Utermann G (1985) Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem 260: 2258–2264

    PubMed  CAS  Google Scholar 

  35. Steinmetz A, Kaffarnik H, Utermann G (1985) Activation of phosphatidylcholine-sterol acyl-transferase by human apolipoprotein E isoforms. Eur J Biochem 152: 747–751

    Article  CAS  Google Scholar 

  36. Strategies for the prevention of coronary heart disease (1987) A policy statement for the European Atherosclerosis Society. Eur Heart J 8: 77–88

    Google Scholar 

  37. Zorich N, Jonas A, Pownall HJ (1985) Activation of lecithin cholesterol acyltransferase by human apolipoprotein E in discoidal complexes with lipids. J Biol Chem 260: 8831–8837

    CAS  Google Scholar 

Download references

Authors
  1. A. Steinmetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abtl. Endokrinologie u. Stoffwechsel Zentrum Innere Medizin, Universität Marburg, Baldinger Straße, D-3550, Marburg, Germany

    Hans Kaffarnik , Jürgen Schneider  & Armin Steinmetz ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Steinmetz, A. (1988). Epidemiologie und neue Richtwerte zur Behandlung der Hyperlipoproteinämien. In: Kaffarnik, H., Schneider, J., Steinmetz, A. (eds) Aktuelle Gesichtspunkte der Hyperlipoproteinämien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73478-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73478-6_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-19023-3

  • Online ISBN: 978-3-642-73478-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation